MRC/UVRI and London School of Hygiene and Tropical medicine Research unit., Uganda

Registration Status: Completed

Objective: The MRC/UVRI and LSHTM Uganda Research Unit on AIDS is an internationally recognized center of excellence for research on HIV infection and related diseases, contributing knowledge on the evolving epidemic, the evaluation of innovative health care options, treatment and prevention, and the development of health policy and practice in Africa and worldwide. The unit was established in 1989 following a request from the Uganda Government to the UK Government to contribute to the understanding and control of the HIV pandemic in Uganda. In 2005, the MRC program was upgraded to a research unit with headquarters in Entebbe at the Uganda Virus Research Institute (UVRI) and the main research activities located in Masaka, Kalungu, Kampala and Wakiso districts, including the peri-urban areas of Entebbe.

Registered Biobank Name	MRC/UVRI and London School of Hygiene and Tropical medicine Research unit.
Biobank Leader	Sureyah Nassimbwa
Country	Uganda
Email for biobank inquiries	Sureyah.Nassimbwa@mrcuganda.org
Principal Investigator	Peter.Hughes@mrcuganda.org
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Oligo - Collection aimed at supporting several research projects, a research group or a research consortium

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).